Eptifibatide derivative and preparation method thereof
The label-assisted liquid phase synthesis of eptifibatide derivatives addresses inefficiencies in traditional methods by reducing material and reagent waste, enabling cost-effective and environmentally friendly large-scale production.
Patent Information
- Application Number
- CN202411282489.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-13
- Publication Date
- 2024-12-06
AI Technical Summary
Existing methods for synthesizing eptifibatide and its derivatives, such as solid phase peptide synthesis (SPPS) and liquid phase peptide synthesis (LPPS), are inefficient, costly, and environmentally harmful due to high material and reagent waste, making large-scale production difficult.
A label-assisted liquid phase synthesis strategy is employed to synthesize eptifibatide derivatives, utilizing tag-assisted peptide liquid phase synthesis (TAPS) to reduce raw material and reagent usage, and incorporate environmentally friendly processes.
This method significantly reduces the consumption of amino acid raw materials and chemical reagents, minimizes waste, and enables efficient batch production of eptifibatide derivatives while aligning with green chemistry principles.
Smart Images

Figure CN119080882A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of pharmaceutical and polypeptide chemical synthesis, and relates to a derivative of eptifibatide and a preparation method thereof. The present invention uses eptifibatide as a basic skeleton and realizes the green synthesis of eptifibatide derivatives simply and efficiently through a label-assisted polypeptide liquid phase synthesis strategy. Background Art
[0002] Acute coronary syndrome is a common cardiovascular disease and a serious type of coronary heart disease. Its main cause is the development of thrombus, which is a pathological manifestation of platelet aggregation. Platelet membrane glycoprotein (GPIIb / IIIa) receptor antagonists can be selectively used in patients with heavy thrombus burden.
[0003] Eptifibatide is a cyclic heptapeptide derived from the venom of the southeastern pygmy rattlesnake. It has high specificity and affinity for GPIIb / IIIa and a short half-life in plasma. Therefore, the preparation of Eptifibatide and its derivatives will promote the development of new antiplatelet aggregation drugs.
[0004] Eptifibatide was originally developed by COR Therapeutic, Inc., and was launched in the United States in 1998. Eptifibatide is a cyclic carbon-terminal amidated polypeptide composed of six amino acids and mercaptopropionic acid. The chemical structure and amino acid sequence structure are shown below.
[0005]
[0006] At present, the preparation of eptifibatide and its derivatives is mainly carried out through solid phase peptide synthesis (SPPS) technology and liquid phase peptide synthesis (LPPS) technology. Solid phase peptide synthesis technology is a heterogeneous peptide amide coupling reaction that occurs in solution using a polymer resin as a carrier for the synthesis of eptifibatide. Therefore, a 2-3 times excess of amino acid raw materials is required in each coupling step to achieve the maximum reaction, resulting in a great waste of amino acid raw materials and coupling reagents. After the coupling is completed, a large amount of solvent is required to wash the resin, which increases the synthesis cost of eptifibatide and its analogs, and also makes it difficult to prepare eptifibatide in batches and on a large scale. Liquid phase peptide synthesis usually requires the use of chromatography to purify eptifibatide intermediates, and requires the use of a large amount of chemical solvents. The efficiency of synthesizing eptifibatide is low, and LPPS is also difficult to prepare eptifibatide in batches.
[0007] The tag-assisted peptide liquid phase synthesis (TAPS) strategy is a peptide synthesis method that combines the advantages of SPPS and LPPS. It can not only achieve homogeneous chemical reactions, but also purify eptifibatide intermediates through precipitation filtration like SPPS. Compared with the traditional solid-phase peptide synthesis (SPPS) technology, this technology can reduce the use of amino acid raw materials by 2 to 3 times and the use of chemical reagents by 8 to 10 times in the production of eptifibatide APIs, greatly reducing the preparation cost of eptifibatide drugs. At the same time, TAPS technology can reduce the emission of polymer resin pollutants and chemical reagents in solid-phase peptide synthesis, and can achieve green and environmentally friendly benign ecological benefits, which is highly consistent with the opinions of the four national departments jointly issued the "Guiding Opinions on Promoting the Green Development of the API Industry" to further increase the proportion of APIs produced by green processes and significantly increase the market share of high-end specialty APIs.
[0008] Therefore, the synthesis of eptifibatide and its analogs by green TAPS preparation technology is highly consistent with the synthesis concept and innovation of green chemistry. At the same time, the design and synthesis of derivatives based on the basic skeleton of eptifibatide will be of great significance for the subsequent study of the structure-activity relationship of eptifibatide. Summary of the invention
[0009] The purpose of the present invention is to provide an eptifibatide derivative and a preparation method thereof, and to prepare a series of eptifibatide derivatives by a label-assisted liquid phase synthesis strategy capable of synthesizing cyclic peptides in batches.
[0010] The eptifibatide derivative provided by the present invention is a cyclic compound having a structure represented by the following structural formula (I), or a pharmaceutically acceptable salt or prodrug thereof:
[0011]
[0012] in:
[0013] The substituent R1 is selected from C 1~6 Alkylamino, C 1~6 Alkylamide, C 1~6 Alkylurea or C 1~6 Alkylguanidinyl;
[0014] The substituent R2 is selected from hydrogen, amino, or the following amide substituents connected by amide bonds: saturated or unsaturated alkyl fatty amides having no more than 15 carbon atoms, halobenzamides, diphenylcarboxamides, cyanobenzamides, alkylbenzamides, alkoxybenzamides, heterocyclic substituted carboxamides or acetamides;
[0015] The substituent X is selected from NH2 or OH.
[0016] Further, the substituent R1 is selected from C1~4 Alkylamino, C 1~4 Alkylamide, C 1~4 Alkylurea or C 1~4 Alkylguanidinyl.
[0017] Furthermore, the substituent R1 is preferably methylamino, ethylamino, n-propylamino, n-butylamino, acetamido, propionamido, 1-ureapropyl, 1-propylguanidine or 1-butylguanidine.
[0018] Furthermore, the halogenated benzamide in the substituent R2 may be a monohalogenated benzamide or a polyhalogenated benzamide.
[0019] Furthermore, the heterocyclic substituted carboxamide or acetamide in the substituent R2 may preferably be quinoline-2-carboxamide, thiazole-4-carboxamide, (1-imidazolyl)acetamide or 3-methylimidazolium chloroacetamide.
[0020] The present invention also provides a label-assisted liquid phase preparation method of the eptifibatide derivative represented by the above structural formula (I), and the specific preparation method is as follows:
[0021] S1: Liquid phase coupling of Fmoc-protected amino acids with label molecules
[0022] Under the action of coupling reagents, the tag molecule HO-TAG (TAG1) or H2N-Rink-TAG (TAG2) is subjected to esterification reaction or amide coupling reaction with the Fmoc-protected amino acid Fmoc-Cys(Trt)-OH to generate the tag-loaded single peptide intermediate Fmoc-Cys(Trt)-O-TAG or Fmoc-Cys(Trt)-CONH-Rink-TAG;
[0023] S2: Removal of Fmoc protection
[0024] The amino Fmoc protection of the label-loaded single peptide intermediate is removed under the action of a de-Fmoc reagent to obtain a label-loaded de-Fmoc-protected single peptide intermediate NH2-Cys(Trt)-O-TAG or NH2-Cys(Trt)-CONH-Rink-TAG;
[0025] S3: Peptide chain extension
[0026] Using Fmoc-Pro-OH, Fmoc-Trp(Boc)-OH, Fmoc-Asp(tBu)-OH and Fmoc-Gly-OH as raw materials, the amide coupling reaction and amino Fmoc protection removal were repeated under the action of coupling reagents and de-Fmoc reagents to obtain a label-loaded de-Fmoc protected pentapeptide intermediate:
[0027] NH2-Gly-Asp(tBu)-Trp(Boc)-Pro-Cys(Trt)-O-TAG; or
[0028] NH2-Gly-Asp(tBu)-Trp(Boc)-Pro-Cys(Trt)-CONH-Rink-TAG;
[0029] The Fmoc-protected amino acid containing an amino side chain of the following structural formula (II) is then connected by amide coupling reaction:
[0030]
[0031] Wherein the substituent R1 is selected from C 1~6 Alkylamino, C 1~6 Alkylamide, C 1~6 Alkylurea or C 1~6 Alkylguanidinyl; and the amino group on R1 is protected with Boc or Trt or not;
[0032] Then remove the amino Fmoc protection to obtain the label-loaded eptifibatide derivative precursor compound:
[0033] NH2-AA(R1)-Gly-Asp(tBu)-Trp(Boc)-Pro-Cys(Trt)-O-TAG; or
[0034] NH2-AA(R1)-Gly-Asp(tBu)-Trp(Boc)-Pro-Cys(Trt)-CONH-Rink-TAG;
[0035] Wherein, AA(R1) represents a natural or unnatural amino acid with a side chain of R1;
[0036] S4: Preparation of linear eptifibatide derivatives
[0037] The label-loaded linear eptifibatide derivatives were prepared by one of the following methods:
[0038] 1) Using Mpa(Trt)-OH as raw material, an amide coupling reaction is carried out under the action of a coupling reagent to obtain a linear eptifibatide derivative loaded with a label:
[0039] Mpa(Trt)-AA(R1)-Gly-Asp(tBu)-Trp(Boc)-Pro-Cys(Trt)-O-TAG; or
[0040] Mpa(Trt)-AA(R1)-Gly-Asp(tBu)-Trp(Boc)-Pro-Cys(Trt)-CONH-Rink-TAG;
[0041] 2) Using Fmoc-Cys(Trt)-OH as raw material, an amide coupling reaction is carried out under the action of a coupling reagent, and the amino Fmoc protection is removed to obtain a linear eptifibatide derivative loaded with a label:
[0042] NH2-Cys(Trt)-AA(R1)-Gly-Asp(tBu)-Trp(Boc)-Pro-Cys(Trt)-O-TAG; or
[0043] NH2-Cys(Trt)-AA(R1)-Gly-Asp(tBu)-Trp(Boc)-Pro-Cys(Trt)-CONH-Rink-TAG;
[0044] Then, an amide coupling reaction is carried out with an organic acid R3-COOH under the action of a coupling reagent or without reacting with an organic acid to prepare a label-loaded linear eptifibatide derivative:
[0045] R4-Cys(Trt)-AA(R1)-Gly-Asp(tBu)-Trp(Boc)-Pro-Cys(Trt)-O-TAG;
[0046] R4-Cys(Trt)-AA(R1)-Gly-Asp(tBu)-Trp(Boc)-Pro-Cys(Trt)-CONH-Rink-TAG;
[0047] The substituent R3 is selected from a saturated or unsaturated alkyl group having no more than 14 carbon atoms, a halogenated phenyl group, a biphenyl group, a cyanophenyl group, an alkylphenyl group, an alkoxyphenyl group, a 2-quinolyl group, a 4-thiazolyl group, a (1-imidazolyl)methylene group or a 3-methylimidazolium chloromethylene group;
[0048] The substituent R4 is a carbonyl group connected to the linker of R3;
[0049] That is, when the substituent R2 in the structural formula (I) is an amide substituent group connected via an amide bond, it is formed by connecting an imino group to the carbonyl group of R4, or connecting an amide group to the linking group of R3;
[0050] S5. Peptide chain cleavage
[0051] The linear eptifibatide derivative loaded with the tag is used as a raw material, and an acidic cleavage reagent is used for cleavage treatment to remove the TAG group and the tBu, Boc, and Trt protecting groups of the side chain to obtain an unprotected linear eptifibatide derivative:
[0052] Mpa-AA(R1)-Gly-Asp-Trp-Pro-Cys-COX; or
[0053] NH2-Cys-AA(R1)-Gly-Asp-Trp-Pro-Cys-COX; or
[0054] R4-Cys-AA(R1)-Gly-Asp-Trp-Pro-Cys-COX;
[0055] Wherein, when the tag molecule HO-TAG (TAG1) is used, the substituent X is OH, and when the tag molecule H2N-Rink-TAG (TAG2) is used, the substituent X is NH2;
[0056] S6. Oxidative cyclization of peptide chains
[0057] The unprotected linear eptifibatide derivative is used as a raw material, and the linear eptifibatide derivative is cyclized under the action of a cyclization reagent to obtain a target eptifibatide derivative having a structure shown in structural formula (I).
[0058] In the present invention, various amino acid raw materials used in the preparation of the eptifibatide derivatives are protected by using fluorenylmethoxycarbonyl (Fmoc) to protect the α-amino group of natural or non-natural amino acids. In addition, the active side chain groups on the amino acids can also be protected, including but not limited to the following conventional group protection methods: using tert-butyl (tBu) to protect the side chain carboxyl group, using tert-butyloxycarbonyl (Boc) to protect the side chain amino group, using trityl (Trt) to protect the side chain thiol group, etc.
[0059] The reagents used in the esterification reaction of the present invention are various conventional esterification coupling reagents, and the present invention has no special limitation thereto. Preferably, the esterification coupling reagent combination used in the present invention is one of EDCl / DMAP, DIC / DMAP, and DCC / DMAP.
[0060] The coupling reagent used in the amide coupling reaction of the present invention is any conventional coupling reagent, and the present invention has no special limitation thereto. Preferably, the coupling reagent used in the present invention is any one of the combination reagents such as EDCl / HOBt, EDCl / HOBt / DIPEA, DIC / HOBt, DCC / HOSU, HATU / DIPEA, and PyBOP / DIPEA.
[0061] More specifically, the esterification reaction and amide coupling reaction of the present invention are preferably stirred at 0 to 40° C. for 1 to 10 hours.
[0062] Furthermore, the medium for the esterification reaction and the amidation coupling reaction of the present invention is a solvent that can produce good phase separation with water, and the solvent includes but is not limited to one or more of chloroform, dichloromethane, etc.
[0063] Furthermore, in the preparation method of the present invention, the removal of amino Fmoc protection is specifically carried out by using a conventional organic base Fmoc removal reagent at 0-25°C for 0.5-1h.
[0064] Furthermore, the Fmoc removal reagent is any one of a mixed solution of diethylamine / acetonitrile and piperidine / acetonitrile.
[0065] In the preparation method of the present invention, the linear eptifibatide derivative loaded with the tag is cleaved for 2 to 3 hours using an acidic cleavage reagent to remove the TAG group, the Boc, tBu, and Trt protecting groups of the side chain. The present invention also has no special limitation on the acidic cleavage reagent, which can be various conventional acidic cleavage reagents, such as a combination of trifluoroacetic acid / triisopropylsilane / aqueous solution, or a combination of trifluoroacetic acid / triisopropylsilane / water / thioanisole solution.
[0066] Furthermore, the present invention precipitates and purifies the unprotected linear eptifibatide derivative after cleavage with a cold ether solvent, and then performs oxidation cyclization to obtain the target eptifibatide derivative. The cold ether solvent is one or more of cold ethyl ether, cold isopropyl ether, and cold methyl tert-butyl ether.
[0067] Furthermore, the oxidative cyclization of the linear eptifibatide derivative of the present invention uses H2O2 as an oxidizing agent and reacts in a water / acetonitrile mixed solution with stirring for 0.5 to 1 hour.
[0068] The present invention adopts preparative liquid chromatography to finally purify the eptifibatide derivative.
[0069] The present invention refers to the eptifibatide backbone molecule and prepares a series of eptifibatide derivatives through a label-assisted liquid-phase peptide synthesis strategy. Compared with traditional solid-phase peptide synthesis and liquid-phase peptide synthesis techniques, this strategy can maximize the reduction of the use of amino acid raw materials and chemical reagents, and avoid the discharge of chemical wastes such as polymer resins. BRIEF DESCRIPTION OF THE DRAWINGS
[0070] Figure 1 This is a high-resolution mass spectrum of eptifibatide derivative 1.
[0071] Figure 2 This is a high-resolution mass spectrum of eptifibatide derivative 9.
[0072] Figure 3 This is a high-resolution mass spectrum of eptifibatide derivative 10.
[0073] Figure 4 This is a high-resolution mass spectrum of eptifibatide derivative 28. Implementation
[0074] The following embodiments are further described in detail in conjunction with the accompanying drawings and examples. The following examples are only used to more clearly illustrate the technical solution of the present invention so that those skilled in the art can understand and utilize the present invention well, but not to limit the scope of protection of the present invention.
[0075] The production processes, experimental methods or detection methods involved in the embodiments of the present invention, unless otherwise specified, are all conventional methods in the prior art, and their names and / or abbreviations are all conventional names in the field, and are very clear and unambiguous in the relevant application fields. Technical personnel in the field can understand the conventional process steps based on the names and apply the corresponding equipment, and implement them according to conventional conditions or the conditions recommended by the manufacturer.
[0076] The various instruments, equipment, raw materials or reagents used in the embodiments of the present invention are not particularly limited in terms of their sources, and are all conventional products that can be purchased through regular commercial channels, or can be prepared according to conventional methods well known to those skilled in the art.
[0077] The present invention provides an eptifibatide derivative, which is a cyclic compound having a structure shown in structural formula (I), or a pharmaceutically acceptable salt or prodrug thereof.
[0078]
[0079] in:
[0080] The substituent R1 is selected from C 1~6 Alkylamino, C 1~6 Alkylamide, C 1~6 Alkylurea or C 1~6 Alkylguanidinyl;
[0081] The substituent R2 is selected from hydrogen, amino, or the following amide substituents connected by amide bonds: saturated or unsaturated alkyl fatty amides having no more than 15 carbon atoms, halobenzamides, diphenylcarboxamides, cyanobenzamides, alkylbenzamides, alkoxybenzamides, heterocyclic substituted carboxamides or acetamides;
[0082] The substituent X is selected from NH2 or OH.
[0083] Preferably, the eptifibatide derivative of the present invention may be any one of the eptifibatide derivatives 1 to eptifibatide derivatives 29 described in the following structures, or a pharmaceutically acceptable salt or prodrug thereof.
[0084]
[0085] The eptifibatide cyclic heptapeptide derivative is prepared based on a label-assisted liquid phase preparation method according to the following synthetic route:
[0086] The specific meanings of some commonly used abbreviations appearing in the specification of the present invention are as follows:
[0087] Fmoc: fluorenylmethoxycarbonyl
[0088] tBu: tert-butyl
[0089] Boc: tert-butyloxycarbonyl
[0090] Trt: trityl
[0091] AA: Amino Acid
[0092] EDCl: 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
[0093] DMAP: 4-dimethylaminopyridine
[0094] DIC: 1,3-Diisopropylcarbodiimide
[0095] DCC: N,N-dicyclohexylcarbodiimide
[0096] HOBt: 1-Hydroxybenzotriazole
[0097] DIPEA: N,N-diisopropylethylamine
[0098] HOBt: 1-Hydroxybenzotriazole
[0099] HOSU: N-hydroxysuccinimide
[0100] HATU: O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate
[0101] PyBOP: 1H-Benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate Example
[0102] Example 1
[0103] Step 1: Esterification reaction of TAG1 with Fmoc-Rink-OH to prepare Fmoc-NH-Rink-TAG
[0104] Fmoc-Rink-OH (5.93 g, 11 mmol), EDCl (2.68 g, 14 mmol), and DMAP (244 mg, 2 mmol) were weighed in turn and dissolved in 80 mL of dichloromethane. After stirring for 30 min, 4,4'-diphenylphosphonoxybenzhamethanol tag (TAG-OH, TAG1) (6.16 g, 10 mmol) was added. The mixture was heated to room temperature and stirred for 5 h. The reaction endpoint was detected by TLC.
[0105] The reaction product was washed twice with 10% Na2CO3 solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to 3 mL. 30 mL of petroleum ether was added dropwise to produce a white precipitate and the solution was filtered off. The above precipitation operation was repeated 3 times to obtain purified Fmoc-NH-Rink-TAG.
[0106] Step 2: Removal of Fmoc protection from Fmoc-NH-Rink-TAG to prepare TAG2
[0107] The Fmoc-NH-Rink-TAG in step 1 was dissolved in 9 mL of acetonitrile, 3 mL of diethylamine was added at room temperature, and the mixture was stirred and removed for 30 min. After concentration under reduced pressure, the mixture was dissolved in 3 mL of dichloromethane, 30 mL of petroleum ether was added dropwise to produce a white precipitate, and the solution was filtered off. The above precipitation operation was repeated 3 times to obtain purified NH2-Rink-TAG (TAG2).
[0108] Step 3: Coupling of TAG2 with Fmoc-protected amino acid amides to prepare the labeled linear heptapeptide
[0109] Fmoc-Cys(Trt)-OH (6.15 g, 10.5 mmol), EDCl (2.49 g, 13 mmol), and HOBt (1.48 g, 11 mmol) were weighed in sequence and dissolved in 80 mL of dichloromethane. After stirring for 30 min, TAG2 obtained in step 2 was added and the reaction was continued with stirring for 1 h. The reaction endpoint was detected by TLC.
[0110] The reaction product was washed with 10% Na2CO3 solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to 3 mL. 30 mL of petroleum ether was added dropwise to produce a white precipitate and the solution was filtered off. The above precipitation operation was repeated 3 times to obtain purified Fmoc-Cys(Trt)-CONH-Rink-TAG.
[0111] With the removal of Fmoc protection and amide coupling as one cycle, steps 2 and 3 were repeated, and Fmoc-Pro-OH, Fmoc-Trp(Boc)-OH, Fmoc-Asp(tBu)-OH, Fmoc-Gly-OH, Fmoc-Arg(Pbf)-OH and MPa(Trt)-OH were sequentially connected to Fmoc-Cys(Trt)-CONH-Rink-TAG to prepare the linear heptapeptide MPa(Trt)-Arg(Pbf)-Gly-Asp(tBu)-Trp(Boc)-Pro-Cys(Trt)-CONH-Rink-TAG containing a tag and side chain protecting groups, with an overall yield of about 83%.
[0112] Step 4: Preparation of linear heptapeptide by cleavage and removal of label and side chain protecting groups
[0113] The linear heptapeptide containing the label and the side chain protecting group was added to a 100 mL round-bottom flask, and then 20 mL of trifluoroacetic acid / thioanisole / triisopropylsilane / water (TFA / PhSMe / Tis / H2O, 85 / 10 / 2.5 / 2.5, v / v / v / v ) and the obtained cleavage reagent was mixed and stirred at room temperature for 3 h.
[0114] After the cleavage reaction was completed, the mixture was concentrated under reduced pressure at room temperature to remove most of the trifluoroacetic acid. 15 mL of cold methyl tert-butyl ether was added to the concentrate to precipitate a white precipitate, which was centrifuged and then washed with cold methyl tert-butyl ether and assisted by ultrasonic precipitation, which was repeated 3 times and dried to obtain a linear heptapeptide MPa-Arg-Gly-Asp-Trp-Pro-Cys-CONH2 as a white solid with a yield of 97%.
[0115] Step 5: Preparation of the target product of eptifibatide derivative 1 by linear heptapeptide cyclization
[0116] The linear heptapeptide (817 mg, 1.0 mmol) was dissolved in 100 mL of water and acetonitrile (1:1, v / v ) in a mixed solvent, the pH was adjusted to 9.5 with dilute ammonia water, 1 mL of 3% H2O2 was added, the reaction was stirred at room temperature for 1 h, and the cyclization process was monitored by HPLC. After the cyclization was completed, the reaction was stopped to obtain a crude mixed solution of eptifibatide derivative 1.
[0117] The crude mixture was concentrated and 18The product was purified by preparative chromatography (chromatographic conditions: mobile phase: acetonitrile / water 0.1% TFA; wavelength 215 nm, flow rate 5 mL / min), and the eptifibatide derivative 1 with the following structure was obtained at a retention time of 7.000 min with a yield of 67%.
[0118]
[0119] The mass spectrum of the product is as follows Figure 1 , HRMS (ESI) m / z calcd for C 34 H 48 N 11 O9S2 + (M+H) + 818.30724, found 818.30713.
[0120] Example 2
[0121] The eptifibatide derivative was synthesized in the same manner as in Example 1, except that the arginine (Arg) at position 2 was replaced by asparagine (Asn).
[0122] The cyclization product was purified by chromatography to obtain the eptifibatide derivative 2 with the following structure with HPLC retention time t=7.134 min and a yield of 65%.
[0123]
[0124] HRMS (ESI) m / z calcd for C 32 H 42 N9O 10 S2 + (M+H) + 776.24906, found776.24902.
[0125] Example 3
[0126] The eptifibatide derivative was synthesized in the same manner as in Example 1, except that the arginine (Arg) at position 2 was replaced by citrulline (Cit).
[0127] The cyclization product was purified by chromatography to obtain the eptifibatide derivative 3 with the following structure with HPLC retention time t=7.246 min and a yield of 66%.
[0128]
[0129] HRMS (ESI) m / z calcd for C 34 H 47 N 10 O10 S2 + (M+H) + 819.29126, found819.29132.
[0130] Example 4
[0131] The eptifibatide derivative was synthesized in the same manner as in Example 1, except that the arginine (Arg) at position 2 was replaced by 2,4-diamino-butyric acid (Dab).
[0132] The cyclization product was purified by chromatography to obtain the eptifibatide derivative 4 with the following structure with HPLC retention time t=6.494 min and a yield of 66%.
[0133]
[0134] HRMS (ESI) m / z calcd for C 32 H 44 N9O9S2 + (M+H) + 762.26979, found 762.26965.
[0135] Example 5
[0136] The eptifibatide derivative was synthesized in the same manner as in Example 1, except that the arginine (Arg) at position 2 was replaced by 2,3-diamino-propionic acid (Dap).
[0137] The cyclization product was purified by chromatography to obtain the eptifibatide derivative 5 with the following structure with HPLC retention time t=6.390 min and a yield of 65%.
[0138]
[0139] HRMS (ESI) m / z calcd for C 31 H 42 N9O9S2 + (M+H) + 748.25414, found 748.25409.
[0140] Example 6
[0141] The eptifibatide derivative was synthesized in the same manner as in Example 1, except that the arginine (Arg) at position 2 was replaced by glutamine (Gln).
[0142] The cyclization product was purified by chromatography to obtain the eptifibatide derivative 6 with the following structure with HPLC retention time t=6.989 min and a yield of 67%.
[0143]
[0144] HRMS (ESI) m / z calcd for C 33 H 44 N9O 10 S2 + (M+H) + 790.26471, found790.26501.
[0145] Example 7
[0146] The eptifibatide derivative was synthesized in the same manner as in Example 1, except that the arginine (Arg) at position 2 was replaced by lysine (Lys).
[0147] The cyclization product was purified by chromatography to obtain the eptifibatide derivative 7 with the following structure with HPLC retention time t=6.733 min and a yield of 66%.
[0148]
[0149] HRMS (ESI) m / z calcd for C 34 H 48 N9O9S2 + (M+H) + 790.30109, found 790.30072.
[0150] Example 8
[0151] The eptifibatide derivative was synthesized in the same manner as in Example 1, except that the arginine (Arg) at position 2 was replaced by ornithine (Orn).
[0152] The cyclization product was purified by chromatography to obtain the eptifibatide derivative 8 with the following structure with HPLC retention time t=6.586 min and a yield of 66%.
[0153]
[0154] HRMS (ESI) m / z calcd for C 33 H 46 N9O9S2 + (M+H) + 776.28544, found776.28522.
[0155] Example 9
[0156] Step 1: TAG2 was coupled with Fmoc-protected amino acid amide to prepare a linear heptapeptide containing a tag.
[0157] Fmoc-Cys(Trt)-OH (6.15 g, 10.5 mmol), EDCl (2.49 g, 13 mmol), and HOBt (1.48 g, 11 mmol) were weighed and dissolved in 80 mL of dichloromethane. After stirring for 30 min, TAG2 prepared in Example 1 was added, and the stirring reaction was continued for 1 h. The reaction endpoint was detected by TLC.
[0158] The reaction product was washed with 10% Na2CO3 solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to 3 mL. 30 mL of petroleum ether was added dropwise to produce a white precipitate and the solution was filtered off. The above precipitation operation was repeated 3 times to obtain purified Fmoc-Cys(Trt)-CONH-Rink-TAG.
[0159] Fmoc-Cys(Trt)-CONH-Rink-TAG was dissolved in 9 mL of acetonitrile, 3 mL of diethylamine was added at room temperature, and the mixture was stirred and removed for 30 min. After concentration under reduced pressure, the mixture was dissolved in 3 mL of dichloromethane, 30 mL of petroleum ether was added dropwise to produce a white precipitate and the solution was filtered off. The above precipitation operation was repeated 3 times to obtain purified NH2-Cys(Trt)-CONH-Rink-TAG.
[0160] The amide coupling reaction was repeated with Fmoc-Pro-OH, Fmoc-Trp(Boc)-OH, Fmoc-Asp(tBu)-OH, Fmoc-Gly-OH and Fmoc-HArg(Pbf)-OH in sequence, and the Fmoc protecting group was removed to prepare the linear hexapeptide NH2-HArg(Pbf)-Gly-Asp(tBu)-Trp(Boc)-Pro-Cys(Trt)-CONH-Rink-TAG containing a tag and side chain protecting groups.
[0161] Finally, Cys(Trt)-OH was connected by amide coupling reaction to prepare the linear heptapeptide NH2-Cys(Trt)-HArg(Pbf)-Gly-Asp(tBu)-Trp(Boc)-Pro-Cys(Trt)-CONH-Rink-TAG containing a tag and side chain protecting groups.
[0162] Step 2: Cleavage and removal of the label and side chain protecting groups to prepare a linear heptapeptide.
[0163] The linear heptapeptide containing the label and the side chain protecting group was added to a 100 mL round-bottom flask, and then 20 mL of trifluoroacetic acid / thioanisole / triisopropylsilane / water (TFA / PhSMe / Tis / H2O, 85 / 10 / 2.5 / 2.5, v / v / v / v ) and the obtained cleavage reagent was mixed and stirred at room temperature for 3 h.
[0164] After the cleavage reaction was completed, the mixture was concentrated under reduced pressure at room temperature to remove most of the trifluoroacetic acid. 15 mL of cold methyl tert-butyl ether was added to the concentrate to precipitate a white precipitate, which was centrifuged and then washed with cold methyl tert-butyl ether and assisted by ultrasonic precipitation, which was repeated 3 times and dried to obtain a linear heptapeptide NH2-Cys-HArg-Gly-Asp-Trp-Pro-Cys-CONH2 as a white solid.
[0165] Step 3: Preparation of eptifibatide derivative 9 by cyclization of the linear heptapeptide.
[0166] The linear heptapeptide (817 mg, 1.0 mmol) was dissolved in 100 mL of water and acetonitrile (1:1, v / v ) in a mixed solvent, the pH was adjusted to 9.5 with dilute ammonia water, 1 mL of 3% H2O2 was added, the reaction was stirred at room temperature for 1 h, and the cyclization process was monitored by HPLC. After the cyclization was completed, the reaction was stopped to obtain a crude mixed solution of eptifibatide derivative 9.
[0167] The crude mixture was concentrated and 18 The eptifibatide derivative 9 with the following structure was obtained at a retention time of 3.506 min by preparative column purification (chromatographic conditions: mobile phase acetonitrile / water 0.1% TFA; wavelength 215 nm, flow rate 5 mL / min) with a yield of 64%.
[0168]
[0169] The mass spectrum of the product is as follows Figure 2 , HRMS (ESI) m / z calcd for C 35 H 51 N 12 O9S2 + (M+H) + 847.33379, found 847.33337.
[0170] Example 10
[0171] Weigh n-octanoic acid (158.6 mg, 1.1 mmol), EDCl (229.2 mg, 1.2 mmol), and HOBt (162 mg, 1.2 mmol) and dissolve them in 20 mL of dichloromethane. Add 1 mmol of the linear heptapeptide containing a label and a side chain protecting group prepared in Example 9. Stir the reaction for 2 h. Detect the reaction endpoint by TLC.
[0172] The above product was then added to a 100 mL round-bottom flask, and 10 mL of trifluoroacetic acid / thioanisole / triisopropylsilane / water (TFA / PhSMe / Tis / H2O, 85 / 10 / 2.5 / 2.5, v / v / v / v ) and the obtained cleavage reagent was mixed and stirred at room temperature for 3 h.
[0173] After the cleavage reaction was completed, the solution was concentrated under reduced pressure at room temperature to remove most of the trifluoroacetic acid. 10 mL of cold methyl tert-butyl ether was added to the concentrate to precipitate a white precipitate, which was centrifuged and then washed with cold methyl tert-butyl ether and assisted with ultrasonic precipitation. This was repeated three times and dried to obtain the linear peptide C7H 15 -CONH-Cys-HArg-Gly-Asp-Trp-Pro-Cys-CONH2 white solid.
[0174] The above linear peptide was dissolved in water and acetonitrile (1:1, v / v ) in a mixed solvent, the pH was adjusted to 9.5 with dilute ammonia water, 1 mL of 3% H2O2 was added, the reaction was stirred at room temperature for 1 h, and the cyclization process was monitored by HPLC. After the cyclization was completed, the reaction was stopped to obtain a crude mixed solution of eptifibatide derivative 10.
[0175] The crude mixture was purified by chromatography to obtain the eptifibatide derivative 10 with the following structure with HPLC retention time t=15.929 min and a yield of 61%.
[0176]
[0177] The mass spectrum of the product is as follows Figure 3 , HRMS (ESI) m / z calcd for C 43 H 65 N 12 O 10 S2 + (M+H) + 973.43825, found 973.43842.
[0178] Embodiment 11
[0179] The eptifibatide derivative was synthesized in the same manner as in Example 10, except that the organic acid was replaced by isooctanoic acid from n-octanoic acid.
[0180] The cyclization product was purified by chromatography to obtain the eptifibatide derivative 11 with the following structure with HPLC retention time t=13.805 min and a yield of 60%.
[0181]
[0182] HRMS (ESI) m / z calcd for C 43 H 65 N 12 O 10 S2 + (M+H) + 973.43825, found 973.43848.
[0183] Example 12
[0184] The eptifibatide derivative was synthesized in the same manner as in Example 10, except that the organic acid was replaced by p-fluorobenzoic acid instead of n-octanoic acid.
[0185] The cyclization product was purified by chromatography to obtain the eptifibatide derivative 12 with the following structure with HPLC retention time t=10.547 min and a yield of 58%.
[0186]
[0187] HRMS (ESI) m / z calcd for C 42 H 54 FN 12 O 10 S2 + (M+H) + 969.35058, found969.35101.
[0188] Example 13
[0189] The eptifibatide derivative was synthesized in the same manner as in Example 10, except that the organic acid was replaced by p-chlorobenzoic acid instead of n-octanoic acid.
[0190] The cyclization product was purified by chromatography to obtain the eptifibatide derivative 13 with the following structure with HPLC retention time t=12.241 min and a yield of 57%.
[0191]
[0192] HRMS (ESI) m / z calcd for C 42 H 54 C1N 12 O 10 S2 + (M+H)+ 985.32103, found 985.32141.
[0193] Embodiment 14
[0194] The eptifibatide derivative was synthesized in the same manner as in Example 10, except that the organic acid was replaced by p-bromobenzoic acid instead of n-octanoic acid.
[0195] The cyclization product was purified by chromatography to obtain the eptifibatide derivative 14 with the following structure with HPLC retention time t=12.728 min and a yield of 55%.
[0196]
[0197] HRMS (ESI) m / z calcd for C 42 H 54 Bn 12 O 10 S2 + (M+H) + 1029.27052, found1029.27136.
[0198] Embodiment 15
[0199] The eptifibatide derivative was synthesized in the same manner as in Example 10, except that the organic acid was replaced by 2,4-difluorobenzoic acid instead of n-octanoic acid.
[0200] The cyclization product was purified by chromatography to obtain the eptifibatide derivative 15 with the following structure with HPLC retention time t=10.634 min and a yield of 55%.
[0201]
[0202] HRMS (ESI) m / z calcd for C 42 H 53 F2N 12 O 10 S2 + (M+H) + 987.34116, found 987.34119.
[0203] Example 16
[0204] The eptifibatide derivative was synthesized in the same manner as in Example 10, except that the organic acid was replaced by 2,4-dichlorobenzoic acid instead of n-octanoic acid.
[0205] The cyclization product was purified by chromatography to obtain the eptifibatide derivative 16 with the following structure with HPLC retention time t=12.732 min and a yield of 54%.
[0206]
[0207] HRMS (ESI) m / z calcd for C 42 H 53 C l2 N 12 O 10 S2 + (M+H) + 1019.28206, found1019.28253.
[0208] Embodiment 17
[0209] The eptifibatide derivative was synthesized in the same manner as in Example 10, except that the organic acid was replaced by p-cyanobenzoic acid from n-octanoic acid.
[0210] The cyclization product was purified by chromatography to obtain the eptifibatide derivative 17 with the following structure with HPLC retention time t=9.770 min and a yield of 57%.
[0211]
[0212] HRMS (ESI) m / z calcd for C 43 H 54 N 13 O 10 S2 + (M+H) + 976.35525, found 976.35541.
[0213] Embodiment 18
[0214] The eptifibatide derivative was synthesized in the same manner as in Example 10, except that the organic acid was replaced by phenylpropionic acid from n-octanoic acid.
[0215] The cyclization product was purified by chromatography to obtain the eptifibatide derivative 18 with the following structure with HPLC retention time t=11.661 min and a yield of 55%.
[0216]
[0217] HRMS (ESI) m / z calcd for C 44 H 59 N 12 O 10 S2 +(M+H) + 979.39130, found 979.39172.
[0218] Embodiment 19
[0219] The eptifibatide derivative was synthesized in the same manner as in Example 10, except that the organic acid was replaced by p-methoxybenzoic acid instead of n-octanoic acid.
[0220] The cyclization product was purified by chromatography to obtain the eptifibatide derivative 19 with the following structure with HPLC retention time t=10.100 min and a yield of 57%.
[0221]
[0222] HRMS (ESI) m / z calcd for C 43 H 58 N 12 O 11 S2 2+ (M+2H) 2+ 491.18892, found 491.18903.
[0223] Embodiment 20
[0224] The eptifibatide derivative was synthesized in the same manner as in Example 10, except that the organic acid was replaced by biphenyl-4-carboxylic acid instead of n-octanoic acid.
[0225] The cyclization product was purified by chromatography to obtain the eptifibatide derivative 20 with the following structure with HPLC retention time t=15.998 min and a yield of 55%.
[0226]
[0227] HRMS (ESI) m / z calcd for C 48 H 59 N 12 O 10 S2 + (M+H) + 1027.39130, found1027.39124.
[0228] Embodiment 21
[0229] The eptifibatide derivative was synthesized in the same manner as in Example 10, except that the organic acid was replaced by biphenyl-2-carboxylic acid from n-octanoic acid and the amide coupling reagent was replaced by HATU / DIPEA.
[0230] The cyclization product was purified by chromatography to obtain the eptifibatide derivative 21 with the following structure with HPLC retention time t=13.261 min and a yield of 52%.
[0231]
[0232] HRMS (ESI) m / z calcd for C 48 H 59 N 12 O 10 S2 + (M+H) + 1027.3913038, found1027.39172.
[0233] Embodiment 22
[0234] The eptifibatide derivative was synthesized in the same manner as in Example 10, except that the organic acid was replaced by 1-adamantaneacetic acid instead of n-octanoic acid.
[0235] The cyclization product was purified by chromatography to obtain the eptifibatide derivative 22 with the following structure with HPLC retention time t=17.618 min and a yield of 58%.
[0236]
[0237] HRMS (ESI) m / z calcd for C 47 H 67 N 12 O 10 S2 + (M+H) + 1023.45390, found1023.45471.
[0238] Embodiment 23
[0239] The eptifibatide derivative was synthesized in the same manner as in Example 10, except that the organic acid was replaced by n-tetradecanoic acid from n-octanoic acid.
[0240] The cyclization product was purified by chromatography to obtain the eptifibatide derivative 23 with the following structure with HPLC retention time t=11.247 min and a yield of 48%.
[0241]
[0242] HRMS (ESI) m / z calcd for C 49 H 77 N 12 O10S2 + (M+H) +1057.53215, found1057.53308.
[0243] Embodiment 24
[0244] The eptifibatide derivative was synthesized in the same manner as in Example 10, except that the organic acid was replaced by quinoline-2-carboxylic acid instead of n-octanoic acid.
[0245] The cyclization product was purified by chromatography to obtain the eptifibatide derivative 24 with the following structure with HPLC retention time t=12.498 min and a yield of 63%.
[0246]
[0247] HRMS (ESI) m / z calcd for C 45 H 56 N 13 O 10 S2 + (M+H) + 1002.37090, found1002.37195.
[0248] Embodiment 25
[0249] The eptifibatide derivative was synthesized in the same manner as in Example 10, except that the organic acid was replaced by thiazole-4-carboxylic acid instead of n-octanoic acid.
[0250] The cyclization product was purified by chromatography to obtain the eptifibatide derivative 25 with the following structure with a HPLC retention time of t=8.135 min and a yield of 54%.
[0251]
[0252] HRMS (ESI) m / z calcd for C 39 H 52 N 13 O10S3 + (M+H) + 958.31167, found 958.31293.
[0253] Embodiment 26
[0254] The eptifibatide derivative was synthesized in the same manner as in Example 10, except that the organic acid was replaced by imidazole-1-acetic acid instead of n-octanoic acid.
[0255] The cyclization product was purified by chromatography to obtain the eptifibatide derivative 26 with the following structure with HPLC retention time t=3.518 min and a yield of 59%.
[0256]
[0257] HRMS (ESI) m / z calcd for C 40 H 55 N 14 O 10 S2 + (M+H) + 955.36615, found 955.36737.
[0258] Embodiment 27
[0259] The eptifibatide derivative was synthesized in the same manner as in Example 10, except that the organic acid was replaced by 1-carboxymethyl-3-methylimidazolium chloride from n-octanoic acid.
[0260] The cyclization product was purified by chromatography to obtain the eptifibatide derivative 27 with the following structure with HPLC retention time t=5.927 min and a yield of 47%.
[0261]
[0262] HRMS (ESI) m / z calcd for C 41 H 57 N 14 O 10 S2 + (M) + 969.38180, found 969.38275.
[0263] Embodiment 28
[0264] Fmoc-Cys(Trt)-OH (702 mg, 1.2 mmol), EDCl (229 mg, 1.2 mmol), DMAP (15 mg, 0.12 mmol) and TAG1 (616 mg, 1 mmol) were weighed in turn and dissolved in 20 mL of dichloromethane. After stirring for 30 min, the mixture was transferred to room temperature and stirred for 2 h. The reaction endpoint was detected by TLC.
[0265] The reaction product was washed with 10% Na2CO3 solution, dried over anhydrous sodium sulfate, and concentrated to 1 mL under reduced pressure. 10 mL of petroleum ether was added dropwise to produce a white precipitate and the solution was filtered off. The above precipitation operation was repeated 3 times to obtain purified Fmoc-Cys(Trt)-O-TAG.
[0266] Fmoc-Cys(Trt)-O-TAG was dissolved in 3 mL of acetonitrile, 1 mL of diethylamine was added at room temperature, and the mixture was stirred and removed for 30 min. After concentration under reduced pressure, the mixture was dissolved in 1 mL of dichloromethane, and 10 mL of petroleum ether was added dropwise to produce a white precipitate, which was then filtered off. The above precipitation operation was repeated 3 times to obtain purified NH2-Cys(Trt)-O-TAG.
[0267] Fmoc-Pro-OH (372 mg, 1.1 mmol), EDCl (230 mg, 1.2 mmol), and HOBt (162 mg, 1.2 mmol) were weighed in sequence and dissolved in 20 mL of dichloromethane. The above-obtained NH2-Cys(Trt)-O-TAG was added and stirred for 1 h. The reaction was monitored by TLC.
[0268] The reaction product was washed with 10% Na2CO3 solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to 1 mL. 10 mL of petroleum ether was added dropwise to produce a white precipitate and the solution was filtered off. The above precipitation operation was repeated 3 times to obtain purified Fmoc-Pro-Cys(Trt)-O-TAG.
[0269] With Fmoc removal and amide coupling as one cycle, Fmoc-Trp(Boc)-OH, Fmoc-Asp(tBu)-OH, Fmoc-Gly-OH, Fmoc-HArg(Pbf)-OH and Mpa(Trt)-OH were sequentially connected to Fmoc-Pro-Cys(Trt)-O-TAG to prepare the linear heptapeptide Mpa(Trt)-HArg(Pbf)-Gly-Asp(tBu)-Trp(Boc)-Pro-Cys(Trt)-O-TAG containing a tag and side chain protecting groups.
[0270] The linear heptapeptide containing the label and the side chain protecting group was added to a 50 mL round-bottom flask, and then 10 mL of trifluoroacetic acid / thioanisole / triisopropylsilane / water (TFA / PhSMe / Tis / H2O, 85 / 10 / 2.5 / 2.5, v / v / v / v ) and the obtained cleavage reagent was mixed and stirred at room temperature for 3 h.
[0271] After the cleavage reaction was completed, the solution was concentrated under reduced pressure at room temperature to remove most of the trifluoroacetic acid. 10 mL of cold methyl tert-butyl ether was added to the concentrate to precipitate a white precipitate, which was centrifuged and then washed with cold methyl tert-butyl ether and assisted by ultrasonic precipitation, which was repeated 3 times and dried to obtain a linear heptapeptide MPa-HArg-Gly-Asp-Trp-Pro-Cys-OH as a white solid with a yield of 96%.
[0272] The linear heptapeptide (817 mg, 1.0 mmol) was dissolved in 100 mL of water and acetonitrile (1:1, v / v ) in a mixed solvent, the pH was adjusted to 9.5 with dilute ammonia water, 1 mL of 3% H2O2 was added, the reaction was stirred at room temperature for 1 h, and the cyclization process was monitored by HPLC. After the cyclization was completed, the reaction was stopped to obtain a crude mixed solution of eptifibatide derivative 28.
[0273] The cyclization product was purified by chromatography to obtain eptifibatide derivative 28 with HPLC retention time t=7.757 min and a yield of 62%.
[0274]
[0275] The mass spectrum of the product is as follows Figure 4 , HRMS (ESI) m / z calcd for C 35 H 49 N 10 O 10 S2 + (M+H) + 833.30691, found 833.30688.
[0276] Embodiment 29
[0277] The eptifibatide derivative was synthesized in the same manner as in Example 28, except that the mercaptopropionic acid (Mpa) at position 1 was replaced by cysteine (Cys).
[0278] The cyclization product was purified by chromatography to obtain the eptifibatide derivative 29 with the following structure with HPLC retention time t=3.516 min and a yield of 57%.
[0279]
[0280] HRMS (ESI) m / z calcd for C 35 H 50 N 11 O 10 S2 + (M+H) + 848.31780, found848.31769.
[0281] The above embodiments of the present invention do not describe all the details in detail, nor limit the present invention to the above embodiments. Various changes, modifications, substitutions and variations made by ordinary technicians in this field without departing from the principles and purpose of the present invention should be included in the protection scope of the present invention.
Claims
1. An eptifibatide derivative, which is a cyclic compound having the structure represented by the following structural formula (I), or a pharmaceutically acceptable salt or prodrug thereof: , in: The substituent R1 is selected from C 1~6 Alkylamino, C 1~6 Alkylamide, C 1~6 Alkylurea or C 1~6 Alkylguanidinyl; The substituent R2 is selected from hydrogen, amino, or the following amide substituents connected by amide bonds: saturated or unsaturated alkyl fatty amides having no more than 15 carbon atoms, halobenzamides, diphenylcarboxamides, cyanobenzamides, alkylbenzamides, alkoxybenzamides, heterocyclic substituted carboxamides or acetamides; The substituent X is selected from NH2 or OH.
2. The eptifibatide derivative according to claim 1, characterized in that The substituent R1 is selected from C 1~4 Alkylamino, C 1~4 Alkylamide, C 1~4 Alkylurea or C 1~4 Alkylguanidinyl.
3. The eptifibatide derivative according to claim 1, characterized in that The substituent R1 is selected from methylamino, ethylamino, n-propylamino, n-butylamino, acetamido, propionamido, 1-ureapropyl, 1-propylguanidine or 1-butylguanidine.
4. The eptifibatide derivative according to claim 1, 2 or 3, characterized in that The halobenzamide in the substituent R2 is a monohalogenated benzamide or a polyhalogenated benzamide.
5. The eptifibatide derivative according to claim 1, 2 or 3, characterized in that The heterocyclic substituted carboxamide or acetamide in the substituent R2 is quinoline-2-carboxamide, thiazole-4-carboxamide, (1-imidazolyl)acetamide or 3-methylimidazolium chloroacetamide.
6. The method for preparing the eptifibatide derivative according to claim 1, characterized in that: S1: Liquid phase coupling of Fmoc-protected amino acids with label molecules Under the action of coupling reagents, the tag molecule HO-TAG or H2N-Rink-TAG is subjected to esterification reaction or amide coupling reaction with the Fmoc-protected amino acid Fmoc-Cys(Trt)-OH to generate a tag-loaded single peptide intermediate Fmoc-Cys(Trt)-O-TAG or Fmoc-Cys(Trt)-CONH-Rink-TAG; S2: Removal of Fmoc protection The amino Fmoc protection of the label-loaded single peptide intermediate is removed under the action of a de-Fmoc reagent to obtain a label-loaded de-Fmoc-protected single peptide intermediate NH2-Cys(Trt)-O-TAG or NH2-Cys(Trt)-CONH-Rink-TAG; S3: Peptide chain extension Using Fmoc-Pro-OH, Fmoc-Trp(Boc)-OH, Fmoc-Asp(tBu)-OH and Fmoc-Gly-OH as raw materials, the amide coupling reaction and amino Fmoc protection removal were repeated under the action of coupling reagents and de-Fmoc reagents to obtain a label-loaded de-Fmoc protected pentapeptide intermediate: NH2-Gly-Asp(tBu)-Trp(Boc)-Pro-Cys(Trt)-O-TAG; or NH2-Gly-Asp(tBu)-Trp(Boc)-Pro-Cys(Trt)-CONH-Rink-TAG; The Fmoc-protected amino acid containing an amino side chain of the following structural formula (II) is then connected by amide coupling reaction: , Wherein the substituent R1 is selected from C 1~6 Alkylamino, C 1~6 Alkylamide, C 1~6 Alkylurea or C 1~6 Alkylguanidinyl; and the amino group on R1 is protected with Boc or Trt or not; Then remove the amino Fmoc protection to obtain the label-loaded eptifibatide derivative precursor compound: NH2-AA(R1)-Gly-Asp(tBu)-Trp(Boc)-Pro-Cys(Trt)-O-TAG; or NH2-AA(R1)-Gly-Asp(tBu)-Trp(Boc)-Pro-Cys(Trt)-CONH-Rink-TAG; Wherein, AA(R1) represents a natural or unnatural amino acid with a side chain of R1; S4: Preparation of linear eptifibatide derivatives The label-loaded linear eptifibatide derivatives were prepared by one of the following methods: 1) Using Mpa(Trt)-OH as raw material, an amide coupling reaction is carried out under the action of a coupling reagent to obtain a linear eptifibatide derivative loaded with a label: Mpa(Trt)-AA(R1)-Gly-Asp(tBu)-Trp(Boc)-Pro-Cys(Trt)-O-TAG; or Mpa(Trt)-AA(R1)-Gly-Asp(tBu)-Trp(Boc)-Pro-Cys(Trt)-CONH-Rink-TAG; 2) Using Fmoc-Cys(Trt)-OH as raw material, an amide coupling reaction is carried out under the action of a coupling reagent, and the amino Fmoc protection is removed to obtain a linear eptifibatide derivative loaded with a label: NH2-Cys(Trt)-AA(R1)-Gly-Asp(tBu)-Trp(Boc)-Pro-Cys(Trt)-O-TAG; or NH2-Cys(Trt)-AA(R1)-Gly-Asp(tBu)-Trp(Boc)-Pro-Cys(Trt)-CONH-Rink-TAG; Then, an amide coupling reaction is carried out with an organic acid R3-COOH under the action of a coupling reagent or without reacting with an organic acid to prepare a label-loaded linear eptifibatide derivative: R4-Cys(Trt)-AA(R1)-Gly-Asp(tBu)-Trp(Boc)-Pro-Cys(Trt)-O-TAG; R4-Cys(Trt)-AA(R1)-Gly-Asp(tBu)-Trp(Boc)-Pro-Cys(Trt)-CONH-Rink-TAG; The substituent R3 is selected from a saturated or unsaturated alkyl group having no more than 14 carbon atoms, a halogenated phenyl group, a biphenyl group, a cyanophenyl group, an alkylphenyl group, an alkoxyphenyl group, a 2-quinolyl group, a 4-thiazolyl group, a (1-imidazolyl)methylene group or a 3-methylimidazolium chloromethylene group; The substituent R4 is a carbonyl group connected to the linker of R3; S5. Peptide chain cleavage The linear eptifibatide derivative loaded with the tag is used as a raw material, and an acidic cleavage reagent is used for cleavage treatment to remove the TAG group and the tBu, Boc, and Trt protecting groups of the side chain to obtain an unprotected linear eptifibatide derivative: Mpa-AA(R1)-Gly-Asp-Trp-Pro-Cys-COX; or NH2-Cys-AA(R1)-Gly-Asp-Trp-Pro-Cys-COX; or R4-Cys-AA(R1)-Gly-Asp-Trp-Pro-Cys-COX; Wherein, when the tag molecule HO-TAG is used, the substituent X is OH, and when the tag molecule H2N-Rink-TAG is used, the substituent X is NH2; S6. Oxidative cyclization of peptide chains The unprotected linear eptifibatide derivative is used as a raw material, and the linear eptifibatide derivative is cyclized under the action of a cyclization reagent to obtain a target eptifibatide derivative having a structure shown in structural formula (I).
7. The method for preparing an eptifibatide derivative according to claim 6, characterized in that The esterification reaction and the amide coupling reaction are stirred at 0-40° C. for 1-10 hours.
8. The method for preparing an eptifibatide derivative according to claim 6, characterized in that The removal of amino Fmoc protection is carried out by using an organic base Fmoc removal reagent diethylamine / acetonitrile or piperidine / acetonitrile mixed solution at 0-25° C. for 0.5-1 h.
9. The method for preparing an eptifibatide derivative according to claim 6, characterized in that The label-loaded linear eptifibatide derivative is cleaved for 2 to 3 hours using an acidic cleavage reagent trifluoroacetic acid / triisopropylsilane / water solution combination or a trifluoroacetic acid / triisopropylsilane / water / thioanisole solution combination.
10. The method for preparing an eptifibatide derivative according to claim 6, characterized in that The oxidative cyclization of the linear eptifibatide derivative is carried out by using H2O2 as an oxidizing agent and stirring the reaction in a water / acetonitrile mixed solution for 0.5 to 1 hour.
